DK1401492T3 - LTB4 som vaccineadjuvans - Google Patents

LTB4 som vaccineadjuvans

Info

Publication number
DK1401492T3
DK1401492T3 DK02737698T DK02737698T DK1401492T3 DK 1401492 T3 DK1401492 T3 DK 1401492T3 DK 02737698 T DK02737698 T DK 02737698T DK 02737698 T DK02737698 T DK 02737698T DK 1401492 T3 DK1401492 T3 DK 1401492T3
Authority
DK
Denmark
Prior art keywords
ltb4
vaccine adjuvant
vaccine
enhancing
adjuvant
Prior art date
Application number
DK02737698T
Other languages
Danish (da)
English (en)
Inventor
Pierre Borgeat
Louis Flamand
Jean Gosselin
Original Assignee
Ltb4 Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltb4 Sweden Ab filed Critical Ltb4 Sweden Ab
Application granted granted Critical
Publication of DK1401492T3 publication Critical patent/DK1401492T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Refinement Of Pig-Iron, Manufacture Of Cast Iron, And Steel Manufacture Other Than In Revolving Furnaces (AREA)
  • Vending Machines For Individual Products (AREA)
  • Amplifiers (AREA)
DK02737698T 2001-07-05 2002-06-26 LTB4 som vaccineadjuvans DK1401492T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30270501P 2001-07-05 2001-07-05
PCT/CA2002/000955 WO2003004054A1 (fr) 2001-07-05 2002-06-26 Ltb4 comme adjuvant de vaccin

Publications (1)

Publication Number Publication Date
DK1401492T3 true DK1401492T3 (da) 2009-09-14

Family

ID=23168877

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02737698T DK1401492T3 (da) 2001-07-05 2002-06-26 LTB4 som vaccineadjuvans

Country Status (8)

Country Link
US (1) US7914800B2 (fr)
EP (1) EP1401492B1 (fr)
AT (1) ATE431745T1 (fr)
CA (1) CA2452008C (fr)
DE (1) DE60232413D1 (fr)
DK (1) DK1401492T3 (fr)
ES (1) ES2329118T3 (fr)
WO (1) WO2003004054A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473708B2 (en) 1996-02-15 2009-01-06 Jean Gosselin Agents with leukotriene B4-like antiviral (enveloped RNA) activities
US20050239889A1 (en) * 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
ES2349410T3 (es) * 2004-09-20 2011-01-03 Ltb4 Sweden Ab Formulación farmacéutica de agente de leucotrieno b4 (ltb4) estabilizado.
US20130236496A1 (en) * 2010-06-29 2013-09-12 Universite De Laval Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-i-like receptor ligand, or a nod-like receptor ligand to enhance the innate immune response

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method

Also Published As

Publication number Publication date
ES2329118T3 (es) 2009-11-23
ATE431745T1 (de) 2009-06-15
DE60232413D1 (en) 2009-07-02
CA2452008C (fr) 2012-03-06
WO2003004054A1 (fr) 2003-01-16
CA2452008A1 (fr) 2003-01-16
EP1401492B1 (fr) 2009-05-20
EP1401492A1 (fr) 2004-03-31
US20040208882A1 (en) 2004-10-21
US7914800B2 (en) 2011-03-29

Similar Documents

Publication Publication Date Title
WO2006068663A3 (fr) Compositions de vaccin et procedes permettant de traiter des infections par coronavirus
EP1504112A4 (fr) Mise au point d'un vaccin preventif contre l'infection par filovirus chez les primates
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
ATE426412T1 (de) Adjuvante influenza-vakzine
DE60210456D1 (de) Solubisierung von kapseln polysacchariden
CY2013036I1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
GB2386072A (en) Novel vaccine
ATE521621T1 (de) Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
NO20023935D0 (no) Ny, ikke-antigen, mucosal adjuvantformulering som modulerer effektene av substanser, inkludert vaksineantigener, i kontakt medmucosale kroppsoverflater
DE60015084D1 (de) Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
WO2003041735A3 (fr) Traitement medical
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
GB2444676A (en) Adjuvanted vaccine
DK1395283T3 (da) Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine
WO2003039592A3 (fr) Vaccins cellulaires comprenant des adjuvants
DK1401492T3 (da) LTB4 som vaccineadjuvans
NO20024255L (no) HIV-immun adjuvansterapi
WO2005123112A3 (fr) Procede permettant de renforcer la reponse immunitaire a un vaccin
SG147465A1 (en) Vaccine
WO2006088997A3 (fr) Activites adjuvantes de b-pentameres d'enterotoxine lt-iia et lt-iib
WO2002032455A3 (fr) Vaccin
HU0102823D0 (en) A broad spectrum infectious bursal disease virus vaccine